Literature DB >> 25600806

Midazolam inhibits the formation of amyloid fibrils and GM1 ganglioside-rich microdomains in presynaptic membranes through the gamma-aminobutyric acid A receptor.

Naoki Yamamoto1, Hajime Arima2, Takeshi Sugiura2, Hiroyuki Hirate2, Nobuyoshi Kusama2, Kenji Suzuki3, Kazuya Sobue2.   

Abstract

Recent studies have suggested that a positive correlation exists between surgical interventions performed under general anesthesia and the risk of developing Alzheimer's disease (AD) in the late postoperative period. It has been reported that amyloid β-protein (Αβ) fibrillogenesis, which is closely related to AD, is accelerated by exposure to anesthetics. However, the mechanisms underlying these effects remain uncertain. This study was designed to investigate whether the anesthetic midazolam affects Αβ fibrillogenesis, and if so, whether it acts through GM1 ganglioside (GM1) on the neuronal surface. Midazolam treatment decreased GM1 expression in the detergent-resistant membrane microdomains of neurons, and these effects were regulated by the gamma-aminobutyric acid-A receptor. Midazolam inhibited Αβ fibril formation from soluble Αβ on the neuronal surface. In addition, midazolam suppressed GM1-induced fibril formation in a cell-free system. Moreover, midazolam inhibited the formation of Αβ assemblies in synaptosomes isolated from aged mouse brains. These finding suggested that midazolam has direct and indirect inhibitory effects on Αβ fibrillogenesis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Amyloid β-protein; GM1 ganglioside; Midazolam

Mesh:

Substances:

Year:  2015        PMID: 25600806     DOI: 10.1016/j.bbrc.2015.01.022

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

Review 1.  Stress induced neural reorganization: A conceptual framework linking depression and Alzheimer's disease.

Authors:  Jennifer A Ross; Gediminas Gliebus; Elisabeth J Van Bockstaele
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-08-10       Impact factor: 5.201

Review 2.  Transcranial Magnetic Stimulation in Alzheimer's Disease: Are We Ready?

Authors:  Marina Weiler; Kevin C Stieger; Jeffrey M Long; Peter R Rapp
Journal:  eNeuro       Date:  2020-01-07

3.  Comparison of intravenous sedation using midazolam during dental treatment in elderly patients with/without dementia: a prospective, controlled clinical trial.

Authors:  Yuichi Tatsuno; Yoshinari Morimoto; Megumi Hayashi; Takatoshi Iida
Journal:  Sci Rep       Date:  2021-02-11       Impact factor: 4.379

Review 4.  Targeting the cannabinoid system to counteract the deleterious effects of stress in Alzheimer's disease.

Authors:  Ronnie D Shade; Jennifer A Ross; Elisabeth J Van Bockstaele
Journal:  Front Aging Neurosci       Date:  2022-10-04       Impact factor: 5.702

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.